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Abstract
In agriculture, although fungi are considered the foremost problem, infections by bacteria also cause significant economical
losses. The presence of different diseases in crops often leads to a misuse of the proper therapeutic, or the combination of
different diseases forces the use of more than one pesticide. This work concerns the development of a ‘super-Blad’: a
chimeric protein consisting of Blad polypeptide, the active ingredient of a biological fungicide already on the market, and two
selected peptides, SP10-5 and Sub5, proven to possess biological potential as antibacterial agents. The resulting chimeric
protein obtained from the fusion of Blad with SP10-5 not only maintained strong antibacterial activity, especially against
Xanthomonas spp. and Pseudomonas syringae, but was also able to retain the ability to inhibit the growth of both yeast and
filamentous fungi. However, the antibacterial activity of Sub5 was considerably diminished when fused with Blad, which
seems to indicate that not all fusion proteins behave equally. These newly designed drugs can be considered promising
compounds for use in plant protection. A deeper and focused development of an appropriate formulation may result in a
potent biopesticide that can replace, per se, two conventional chemistries with less impact on the environment.
INTRODUCTION
The quality and yield of crop production have been
adversely affected by a large variety of pests, including bac-
teria, fungi, weeds and insects [1]. Despite the undeniable
role posed by fungi and viruses as the most important plant
pathogens, bacterial infections are increasing and becoming
more severe [2], making them a major threat to agriculture
due to the lack of suitable agrochemicals and the absence of
resistance and/or immunity in host plants. Moreover, they
are usually spread undetected as contaminants or asymp-
tomatic (latent) infections in plant propagation materials
[3]. Another problem is common error when identifying a
plant disease. Manual identification is a somewhat subjec-
tive task and laboratory analyses are often time consuming,
leading to an unacceptable lag between observation and
identification of the disease. Besides, the symptoms of some
diseases are highly heterogeneous, making them difficult to
identify. Moreover, the simultaneous presence of different
diseases may exhibit a combination of symptoms quite dif-
ferent from the each disease per se [4]. As a whole, these fac-
tors often lead to a misinterpretation of the disease which
ultimately leads to a misuse of a proper therapeutic agent,
or the combination of different diseases forces the use of
more than one pesticide.
The abuse and incorrect use of agrochemicals has
resulted in pesticide resistance, pest resurgence, outbreaks
of secondary pests, and pesticide residues in the produce,
soil, air and water [5]. Biopesticides are becoming more
appealing because of their advantages in terms of effective-
ness, environmental safety, specificity, biodegradability and
suitability in integrated pest management (IPM) pro-
grammes. Thus, biopesticides are promising alternatives
in the management of environmental pollutions. The use of
a new generation of microbial biopesticides has registered a
steady annual increase of 10%, and more than 225 micro-
bial biopesticides are registered in 30 Organization for Eco-
nomic Co-operation and Development (OECD) countries
[6]. Nevertheless, biopesticides are still a young and evolv-
ing science where in-depth research is still needed, from
production and formulation to delivery and commercializa-
tion of these products.
For the past few years, antimicrobial peptides have
emerged as promising therapeutic agents in both medicine
and agriculture due to their relatively small size (ease of
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synthesis), their fastness and efficiency, their antimicrobial
activity against a wide range of pathogens and their low tox-
icity for vertebrate cells [7, 8]. However, some studies
have demonstrated that the simultaneous use of more than
one antimicrobial peptide is usually a better approach
toward increasing its effectiveness in plant protection or for
pharmaceutical uses. To achieve this, a simple strategy is to
fuse two protein sequences with the same specialized [9], or
complementary, functions [10, 11], originating a novel pro-
tein called a fusion, or chimeric, protein [12].
Blad is the active ingredient of a biological fungicide already
on the market and discovered by our team. It is a 20.4 kDa
polypeptide, being the major subunit of a 210 kDa glyco-
oligomer, termed Blad-containing oligomer (BCO), which
accumulates in Lupinus albus cotyledons between days 4
and 12 after the onset of germination. The characteristics
that makes the BCO a unique, versatile and multi-functional
protein [13], as well as its powerful and broad-spectrum
antifungal activity towards both plant and human patho-
gens, have been fully discussed [13, 14]. Its mode of action
was also recently described as a multi-site fungicide that dis-
turbs microbial cell homeostasis leading, ultimately, to cell
death [15].
In this work, we report the development of a ‘super-Blad’ –
a fusion gene consisting of the gene that codes for Blad and
genes that code for selected peptides proven to possess bio-
logical potential as antibacterial agents. SP10-5 is a
12-amino acid peptide experimentally designed by Zeitler
and colleagues, using the scorpion-derived antimicrobial
peptide IsCT and the frog-derived peptide mangainin II as
templates [16]. SP10-5 was tested against several bacteria
and presented promising results [16]. Sub5 is a 12-amino
acid cationic peptide synthesized from a linearized variant
of the bovine peptide bactenecin, Bac2A, that acts on the
external membrane of Gram-negative bacteria [17]. Sub5
presents not only antibacterial activity against an array of
both Gram-positive and -negative bacteria, but also antifun-
gal activity against Candida albicans [17, 18].
The current investigation is in line with the new approach
towards producing novel fusion proteins with improved
antimicrobial performance, which may represent the future
of technological development of biopesticides. Here we
report the fusion of two proteins with distinct antimicrobial
properties, one fungicidal and the other bactericidal, creat-
ing a new ‘super-molecule’ that enables simultaneous treat-
ment of fungal and bacterial infections in plants.
METHODS
Strains and media
DH5a-competent Escherichia coli cells were used for all
routine cloning experiments. For recombinant protein over-
expression, C41 (DE3) E. coli strain was used, cultivated in
TB (12 g l 1 tryptone, 24 g l 1 yeast extract, 9.4 g l 1
K2HPO4, 2.2 g l
 1 KH2PO4 and 4ml l
 1 glycerol) medium.
Strains of E. coli, Salmonella thypimurium, Pseudomonas
aeruginosa and Staphylococcus aureus were provided cour-
tesy of Instituto Superior de Agronomia (ISA-UL). Strains
of Xanthomonas arboricola pv. pruni (NCPPB 2878 and
NCPPB 3744), X. versicatoria (NCPPB 3801 and NCPPB
3954) and Pseudomonas syringae pv. tomato (NCPPB 3645
and NCPPB 4369) were purchased from the National
Collection of Plant Pathogenic Bacteria (NCPPB, UK). All
strains were grown at 34 C for 24 h in tryptone soy agar
(TSA) medium [3% (w/v) tryptone soy broth, 1.5 % (w/v)
agar]. For antibacterial susceptibility testing, bacteria were
grown in Mueller–Hinton medium.
C. albicans var. albicans (CBS 562) {CBS: Centraalbureau
voor Schimmelcultures} and C. glabrata (a kind gift from of
the Institute of Microbiology, Faculty of Medicine of the
University of Coimbra [19]) were grown at 34 C for 24 h in
glucose yeast peptone (GYP) medium [1% (w/v) peptone,
0.5 % (w/v) yeast extract, 2% (w/v) glucose and 1.5% (w/v)
agar].
Botrytis cinearea was isolated in our laboratory (from
tomato) and was grown on Sabouraud dextrose agar for
7 days at 25 C. For antifungal susceptibility testing, the
medium used was PDB [2.4 % (w/v) potato dextrose broth],
buffered at pH 7.5.
Plant material
Lupinus albus L. seeds were purchased from Inveja SAS
(France) and were germinated as described by Pinheiro and
colleagues [15].
Production of BCO
Blad-containing oligomer (BCO) was extracted and purified
from 8-day-old cotyledons as previously described [20], and
stored lyophilized at room temperature.
Design of synthetic genes and cloning procedures
Synthetic genes were purchased from GeneScript, Hong
Kong and cloned into pCoofy plasmids, a bacterial expres-
sion vector containing N-terminal 6x His and MBP tags
[21]. General cloning procedures were performed as
described by Scholz and colleagues [22]. The correct nucleo-
tide sequence of the inserts in all the constructed plasmids
was checked by DNA sequencing.
Expression of the fusion proteins
Cells harbouring plasmids encoding the different fusion
proteins were grown overnight at 37 C with shaking, in TB
medium supplemented with kanamycin. For the initial
expression screening, 20 µl of the preculture were inoculated
into 2ml of fresh media on a 24-well plate. For production
upscaling, 10ml of the preculture were used to inoculate 1 l
of fresh media. Inoculates were grown at different tempera-
tures (20, 25, 30 and 37 C) until OD600 nm of 0.4 and then
induced with three different concentrations of IPTG (iso-
propyl b-D-1-thiogalactopyranoside) (0.1, 0.5 and 1mM).
The cells were pelleted after 6 h by centrifugation at 4000 g,
4 C, for 20min.
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Fusion protein purification
Cell pellets were resuspended in lysis buffer (50mM Tris-
HCl pH 8.0, 150mM NaCl and 0.25mgml 1 lysozyme),
submitted to a freeze/thaw cycle and then incubated with
DNase (2.5 µgml 1) and MgCl2 (5mM), thus originating
the total fraction. The soluble and insoluble fractions were
separated by centrifugation (3500 g, 10min, 4 C).
For purification purposes, a MBPTrap HP column (GE
Healthcare) was used, previously equilibrated with 20mM
Tris-HCl at pH 8.0, 2mM ethylenediamine tetraacetic acid
(EDTA), 150mM NaCl and 10% (v/v) glycerol, and eluted
with 10mM maltose in binding buffer.
Solubilization and re-folding of inclusion bodies
The solubilization and re-folding of inclusion bodies was
performed as described by Singh and colleagues [22].
Briefly, the insoluble fraction resulting from the expression
of the fusion proteins was resuspended in wash buffer A
(50mM Tris-HCl pH 8.5, 5mM EDTA, 1mM phenylme-
thylsulfonyl fluoride (PMSF)) and centrifuged at 20 000 g
for 20 min at 4 C. The pellet was resuspended in wash
buffer B (50mM Tris-HCl pH 8.5) and centrifuged again
under the same conditions. The final pellet was resuspended
in milliQ water and kept frozen at  80 C until used. For
solubilization purposes, 5mg of inclusion bodies were sus-
pended in solubilization buffer (50mM Tris-HCl pH 8.5,
5mM EDTA, 1mM PMSF, 8 M urea), mixed by vortexing
and incubated at room temperature for 1 h. The solubilized
proteins were centrifuged at 20 000 g for 30min at 4 C. For
the re-folding, 1ml of the supernatant was added in small
amounts in regular intervals to 9ml of freshly cooled re-
folding buffer (50mM Tris-HCl pH 7.5, 1mM EDTA, 10%
(w/v), 1mM PMSF). The re-folded sample was kept at 4 C
for 6 h and then filtered through a 0.45 µM polyvinylidene
fluoride (PVDF) filter to remove protein aggregates.
Liquid chromatography tandem-mass spectrometry
(LC-MS/MS) analysis
In-gel digestion
The gel bands were sliced into small pieces, de-stained and
incubated overnight with trypsin for protein digestion. Fol-
lowing digestion, peptides were extracted from the gel using
three different solutions of increasing percentages of organic
solvent [water/acetonitrile with 1% (v/v) formic acid]. Pep-
tides were resuspended in 30 µl of a solution containing 2%
(v/v) acetonitrile and 0.1% (v/v) formic acid and analysed
by LC-MS/MS.
LC-MS/MS analysis
Samples were analysed on an AB Sciex 5600 TripleTOF
(ABSciex) in information-dependent acquisition (IDA)
mode. Peptides were fractionated by liquid chromatography
(nanoLC Ultra 2D, Eksigent) on a MicroLC column
ChromXPTM C18CL reverse-phase column (300 µm
ID15 cm length, 3 µm particles, 120 Å pore size, Eksigent)
at 5 µlmin 1 and eluted into the mass spectrometer with an
acetonitrile gradient in 0.1% FA (2 –30%ACN, in a linear
gradient for 30min), using an electrospray ionization source
(DuoSprayTM Source, ABSciex) with a 50 µm internal
diameter (ID) stainless steel emitter (New Objective). For
information-dependent acquisition (IDA) experiments, the
mass spectrometer was set to scanning full spectra (350–
1250m/z) for 250ms, followed by up to 80MS/MS scans
(100–1500m/z from a dynamic accumulation time –
minimum 30ms for precursor above the intensity threshold
of 1000 – in order to maintain a cycle time of 2.7 s). Candi-
date ions with a charge state between +2 and +5 and counts
above a minimum threshold of 10 counts s–1 were isolated
for fragmentation, and one MS/MS spectrum was collected
before adding those ions to the exclusion list for 15 s (mass
spectrometer operated by Analyst TF 1.6, ABSciex). Rolling
collision was used with a collision energy spread of 5.
Protein identification
Protein identification was performed using Protein Pilot
software (v 5.1, ABSciex) with the following parameters:
search against the theoretical sequences of the recombinant
proteins and against the uniprot database from June 2016,
with acrylamide alkylation and trypsin digestion. Positive
identification was considered for proteins that met the 1.3
unused score value and 95% peptide confidence filtering.
Yeast and bacteria inhibition tests
The susceptibility tests were performed according to the
CLSI – Clinical and Laboratory Standards Institute, guide-
lines M27-A2, M31-A2 and M38-A2, for yeasts, bacteria
and filamentous fungi, respectively [23–25] with minor
adjustments.
Bacteria were grown on TSYA medium overnight at 34 C.
The inoculum suspension was then prepared in 5ml of ster-
ile 0.9% (w/v) saline solution (NaCl) and cell density was
adjusted with a spectrophotometer in order to obtain a con-
centration of 1108 cellsml 1. The final inoculum suspen-
sion was made by a 1 : 100 dilution with double-strength
Mueller–Hinton medium, in order to achieve a concentra-
tion of 1106 cellsml 1. The inoculum size was confirmed
by enumeration of c.f.u. on TSYA plates.
The susceptibility tests on yeasts and filamentous fungi were
performed as previously described [13, 14].
In all cases, each well of the microplate contained 100 µl of
the inocula and 100 µl of the diluted drug solution (twofold).
The microplates were incubated at 34 and 25 C for yeasts
and filamentous fungi, respectively, and examined after 72 h.
Bacteria were incubated at 30 C and the results were taken
after 24–72 h, according to their growth rate. The minimum
inhibitory concentration (MIC) endpoints were recorded
visually as the lowest drug concentration that showed absence
of growth. All assays were performed in triplicate.
Electrophoresis and immunoblotting
One-dimensional, sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) and Western blotting were
performed as previously described [20]. For the dot-blot,
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2 µl of each sample were applied to a nitrocellulose mem-
brane (Roche, Mannheim, Germany). Membranes were
blocked with TBST (50mM Tris, 150mM NaCl, 0.1% (v/v)
Tween 20) supplemented with 5% (w/v) skim milk, for 1 h
at room temperature. Membranes were incubated with the
antibody anti-His (Genescript) (1 : 2000) in buffer TBSTM
[TBST, 0.5% (w/v) skim milk] (1 : 10 000) for 1 h, at room
temperature and, after washing, incubated with the antibody
anti-mouse (1 : 10 000) (GE Healthcare, Buckinghamshire,
UK). The detection was performed by degradation of the
ECF substrate (GE Healthcare) and detection on a FX appa-
ratus (Bio-Rad, Hercules, CA).
RESULTS AND DISCUSSION
Production, expression and purification of
recombinant peptide-fusion proteins
The genes that code for both SP10-5 and Sub5 peptides
were fused with the Blad gene to construct the new multi-
factorial peptide-fusion proteins. The fusion of multiple
proteins has already been extensively discussed for biotech-
nological applications [26–32]. Both genes were joined, sep-
arately, to the C-terminal portion of the Blad gene using a
5-amino acid flexible linker (Gly-Gly-Ser-Gly-Gly). Flexible
linkers are usually applied when the joined domains require
a certain degree of movement or interaction. The small size
of these amino acids provides flexibility, and allows for
mobility of the connecting functional domains [33]. The
performance of the newly synthesized fusion protein
depends largely on the peptide liner that is inserted between
the moieties [34–38]. Considering the results obtained in a
previous study where recombinant Blad was successfully
produced in a soluble form in E. coli using MBP (maltose-
binding protein) as a solubility enhancement partner
(unpublished work), the MBP gene was also added to the
construction in the N-terminal end of Blad. MBP has been
successfully used as a solubility-enhancing partner, with
excellent results [39–41] and the additional benefit that it
can also be used as an affinity tag for purification [42, 43].
The design of the peptide-fusion protein construction is
shown in Fig. 1 and the final amino acid sequences are
shown in Fig. S1 (available in the online version of this arti-
cle). MBP has a molecular weight of 40.2 kDa, Blad is
20.4 kDa and SP10-5 and Sub5 are 1.5 and 1.7 kDa, respec-
tively. Therefore, the molecular weight of both peptide-
fusion proteins was approximately 60 kDa.
Both synthetic genes that code for the new peptide-fusion
proteins, hereby termed His6MBPBladSP10-5 and His6
MBPBladSub5, were cloned into pCoofy plasmids, a bacte-
rial expression vector for parallel sequence and ligation
independent cloning (SLIC) containing N-terminal 6x His
and MBP tags [21]. After induction of overexpression of the
genes that code for both peptide-fusion proteins, cells were
collected by centrifugation and analysed by both SDS-
PAGE and immunoblot, using an anti-Histag antibody,
which demonstrated that the genes that code for both pep-
tide-fusion proteins were correctly over-expressed and at
the expected molecular weight (~60 kDa) (data not shown).
To assess the solubility of both peptide-fusion proteins,
both soluble and insoluble fractions were loaded onto a
12% (w/v) SDS-polyacrilamide gel. Fig. 2 shows that both
peptide-fusion proteins were present mainly in the insoluble
fraction under the growth conditions tested.
Another attempt was made to overcome the insolubility
issues. Several expression conditions were tested, including
a combination of four different temperatures (20, 25, 30 and
37 C) with three IPTG concentrations (0.1, 0.5 and 1mM).
After expression under these conditions, both soluble and
insoluble fractions were spotted directly onto a nitrocellu-
lose membrane for dot-blot analysis, using an anti-histag
antibody (Fig. 3). The results obtained revealed that the
majority of the signal is in the insoluble fraction, despite the
temperature or the IPTG concentration tested. The strong
signal observed in the insoluble fraction of both peptide-
fusion proteins is representative of high levels of expression.
However, the fusion proteins were synthesized as inclusion
bodies, meaning that none of the constructs led to signifi-
cant accumulation of the fusion protein in a soluble form.
Despite the accumulated evidence indicating that MBP is a
very promising solubility-enhancing partner [39–41], no
affinity tag is universally ideal and many have the same
downside of yielding different performances with different
partner proteins [43, 44]. Fusing an insoluble protein to a
solubility-enhancing partner does not guarantee a soluble
fusion protein [39].
There are multiple factors that contribute towards the for-
mation of protein aggregates during heterologous expres-
sion in E. coli. Under normal circumstances, one protein
chain is released from the ribosome of E.coli every 35 s and
the macromolecule concentration can reach 300–400mg
ml 1. Under these conditions the correct folding of a pro-
tein can be considered an extraordinary event [45]. In addi-
tion, the newly synthesized recombinant protein is being
synthesized in an environment that may be quite different
from that of its original source in terms of pH, osmolarity,
redox potential, co-factors and folding mechanisms [46].
Finally, it may also be the case that insolubility is an intrin-
sic property of a particular protein [41]. Either way, if a
given protein fails to rapidly achieve its native conformation
Fig. 1. Production of the recombinant peptide-fusion proteins in E.coli. Design of both peptide-fusion proteins.
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there are two possible consequences: partial or complete
deposition into inclusion bodies [45]. Tight control of a
variety of parameters, including temperature of expression,
expression rate and inducer concentration, might help to
reduce the formation of aggregates [37, 43]. In many cases,
the overexpression of genes in E.coli remains an unsolved
Fig. 2. SDS-PAGE analysis of both soluble (S) and the insoluble (I) fractions resulting from the expression of fusions His6
MBPBladSP10-5 (a) and His6MBPBladSub5 (b). Molecular masses of standards are indicated in kDa.
Fig. 3. Dot-blot analysis of both the soluble (S) and insoluble (I) fractions resulting from the expression of fusions His6MBPBladSP10-5








C) with three IPTG concentrations
(a – 1mM, b – 0.5mM and c – 0.1mM).
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problem as the proteins continue to be synthesized as inclu-
sion bodies.
Considering the impossibility of produci both fusion pro-
teins in a soluble form, even with the MBP in the construc-
tion as a solubility-enhancing tag, the next step was to
solubilize and re-fold the inclusion bodies, as described in
Methods. The solubilized peptide-fusion proteins were ana-
lysed by SDS-PAGE (Fig. 4) and the results obtained
revealed that, despite both His6MBPBladSP-10 and His6
MBPBladSub5 being synthesized as inclusion bodies and
thus only soluble in denaturant buffers, it is possible to re-
fold them by slow dilution in a renaturing buffer. Moreover,
Fig. 4 shows that compared to His6MBPBladSP10-5, His6
MBPBladSub5 was recovered at a higher yield considering
the thickness of the respective bands.
The next step was to purify the peptide-fusion proteins. As
mentioned above, MBP not only is a powerful solubility-
enhancing tag that often helps folding of fusion proteins
[47], but also can be used as a detection and a purification
tag [48]. Considering the addition of the MBP into the con-
structs, the purification was performed by affinity chroma-
tography using a MBPTrap HP, a column prepacked with
dextrin, a resin for which MBP has high affinity. The solubi-
lized peptide-fusion proteins were applied to the prepacked
column, washed and eluted with 10mM maltose in binding
buffer and the eluted fractions of both peptide-fusion pro-
teins were analysed by SDS-PAGE (Fig. S2). Analysis of
both the chromatogram and SDS-PAGE revealed that both
fusion proteins were purified to a high level, which is in
accordance with previous studies claiming that purification
by capture affinity step on amylose columns resulted in a
protein that is often 70–90% pure [48, 49].
For the confirmation of the fusion proteins in this study, the
corresponding bands were individually cut from the gel and
analysed by LC-MS/MS. The results obtained from mass
spectrometry analysis were somewhat inconclusive. Taking
into consideration the specific regions for the peptides
SP10-5 and Sub-5 (‘LRIIKKILKKLI’ and ‘RRWKIV-
VIRWRR’, respectively), it was difficult to obtain a good
tryptic peptide for protein identification (trypsin cleaves
after lysines and arginines) and thus to be able to identify
the recombinant peptides. Both Blad and MBP were posi-
tively identified with a 95% confidence level.
Despite the high purity level obtained when purifying both
His6MBPBladSP-10 and His6MBPBladSub5 fusion proteins,
the yields obtained, considering the need to re-fold the
inclusion bodies by diluting them into a re-folding buffer,
were relatively low. In fact, though formation of inclusion
bodies renders protein purification easier, there is no guar-
antee that in vitro re-folding will generate large amounts of
biologically active products [50].
In vitro antimicrobial activity of fusion proteins
In a new set of experiments, the antimicrobial activity of the
fusion proteins His6MBPBladSP10-5 and His6MBPBlad-
Sub5 was evaluated and compared to that of each individual
active compound (SP10-5, Sub-5 and BCO). The results
shown in Table 1 reveal that BCO has a potent antifungal
activity against both yeasts and filamentous fungi, as
expected [13, 14]. However, it was also demonstrated that
BCO has some antibacterial activity, although not strongly
and not against all species. By fusing Blad, the active ingre-
dient of BCO, to a molecule proven to possess biological
potential as an antibacterial agent [16, 17], its spectrum of
action should, theoretically, be enhanced.
Bacterial susceptibility to SP10-5 alone was variable, but its
potent effect towards Xanthomonas spp. and P. syringae was
confirmed [16]. Although Sub5 is described as having con-
siderable antibacterial activity against several species [17,
18], in our study MICs were somewhat higher than
expected, but its efficacy and wide spectrum range were
confirmed. When fused, the activity of SP10-5 (His6
MBPBladSP10-5) was highly enhanced for all bacteria,
becoming particularly efficient against Xanthomonas spp.
and P. syringae. The most extraordinary results were
obtained for E. coli and P. aeruginosa because Blad and
SP10-5 alone were inactive against these species, but their
fusion inhibited bacterial growth. The same occurred with
Sub5 for these species as well as for S. typhimurium. Fur-
thermore, the antibacterial activity of the fusion protein
His6MBPBladSub5 towards the remaining species was
always lower than the corresponding activity of the individ-
ual compounds alone, suggesting a synergistic effect
between these molecules. Comparing the antifungal activity
of both fusion proteins to that of BCO alone, the
Fig. 4. SDS-PAGE analysis of the solubilized inclusion bodies of His6
MBPBladSP10-5 (a) and His6MBPBladSub5 (b). Molecular masses of
standards are indicated in kDa.
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construction was able to retain the ability to inhibit the
growth of both yeasts and filamentous fungi. This was cor-
roborated by the MIC values of Sub-5 and SP10-5 alone for
these strains, which were much higher than those observed
when fused to Blad but similar to the values of BCO alone,
thus confirming that the antifungal activity of the hybrid
proteins derives exclusively from Blad. The antimicrobial
activity of the isolated MBP was tested and revealed no
influence on the results (data not shown).
Fusion proteins are now extensively used in the biomedical
field as an important tool to detect and purify antibodies
[51], and to design and produce bifunctional enzymes [52].
In this work, we designed and investigated the antimicrobial
activity of the fusion proteins His6MBPBladSP10-5 and
His6MBPBladSub5 against important plant pathogens. Both
fusions were constructed with the peptide genes fused to the
C-terminal portion of Blad using a 5-amino acid flexible
linker (oligopeptide) that is widely used to construct func-
tional fusion proteins. As the name implies, flexible linkers
are composed of flexible amino acid residues such as gly-
cine, serine and proline, which allows contiguous proteins
to move independently [10].
It is difficult to express antimicrobial proteins in bacteria,
simply because the active antimicrobial proteins will kill the
host. One possible approach is to force the expression of the
target protein as an inclusion body [53, 54] which, unwit-
tingly, was the case here from the beginning. Thus, we were
able to express a bactericidal peptide in E. coli without
compromising its viability. However, it is well known that
even after successful expression of antimicrobial fusion pro-
teins, they constantly present diminished or absent antimi-
crobial activity [9]. In addition, our results seem to indicate
that not all fusion proteins behave equally; when fusing
genes that code for two different proteins, one can eventu-
ally be produced with impaired bioactivity. Despite the idea
that the choice of the component proteins is based only on
the desired functions of the fusion protein and that, in most
cases, is relatively straightforward [33], the design of fusion
proteins with desired and predictable behaviour remains a
daunting challenge [32].
In this work, both constructions retained the ability to
inhibit the growth of both yeasts and filamentous fungi and,
most importantly, both showed increased antibacterial
activity, probably due to a synergistic effect between Blad
and SP10-5 and Sub5. Hongbiao et al. [9] and Lee et al. [10]
had already successfully engineered hybrid proteins from
two antibacterial peptides. However, the originated fusion
proteins presented inferior antibacterial activity compared
to the individual parental ones. In a similar study published
recently by Kovalskaya et al. [11], a hybrid protein, named
SAP, was also successfully produced but, in this case, it
showed distinct and enhanced biological activities. The
results indicate that the performance of the hybrid protein
was better than or equal to that of the parental proteins. The
work reported by Kovalskaya et al. [11] also demonstrated
that the chimeric protein SAP produced in tobacco and
potato plants had a plant-protective role against Colletotri-
chum coccoides, the casual fungal agent of potato anthrac-
nose, and Clavibacter michiganensis subsp. sepedonicus,
which is the bacterium that causes potato ring rot disease.
Although this proved to be a very interesting study, the ulti-
mate purpose of the authors was to develop a genetic strat-
egy to express the hybrid protein SAP as a self-cleavage
protein in plant cells to allow the production of individual
antimicrobial proteins and, in this way, increase plant path-
ogen resistance. Our work aimed at generating a new mole-
cule to be used as an active ingredient for plant protection
as a plant foliar biopesticide. For a new biopesticide to be of
plant protection interest, high efficiency needs to be com-
bined with low toxicity. Although the toxicological profile
of the hybrid proteins was not assessed in this study, both
the BCO and the individual peptides were previously
Table 1. In vitro susceptibility of various species of bacteria, yeasts and filamentous fungi to the fusion proteins His6MBPBladSP10-5 and His6
MBPBladSub5 and to SP10-5, Sub5 and BCO, as determined by MIC (minimum inhibitory concentration)
Species* (no. of strains) MIC range (µM)
SP10-5 His6MBPBladSP10-5 Sub5 His6MBPBladSub5 BCO
X. arboricola (2) 1.3–5.3 0.065 0.6–2.4 1.032–0.516 1.2–2.4
X. vesicatoria (2) 1.3–5.3 0.065 0.6–1.2 1.032 2.4
E. coli (1) >13 0.516 4.7 NA NA
S. typhimurium (1) 13 0.258 9.4 NA NA
P. aeruginosa (1) >13 0.516 9.4 NA NA
P. syringae (2) 1.3 0.065 1.2 1.032 0.6–1.2
S. aureus (1) 13 1.032 9.4 1.032 2.4
C. albicans (1) 13 0.032 37.6 0.065 0.074
C. glabrata (1) 42.7 0.065 >37.6 0.032 0.074
B. cinerea (1) 42.7 0.065 37.6 0.065 0.149
NA, No activity within the range of concentrations tested.
* B. Botrytis, C. Candida, E. Escherichia, P. Pseudomonas, S. Salmonella, X. Xanthomonas.
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recognized as compounds of low toxicity. In the study
recently published by Pinheiro et al. [15], BCO showed no
evidence of topical toxicity, genotoxicity and carcinogenicity
towards mammalian cells after acute or short-term expo-
sure. In addition, BCO safety as a plant protection product
has been corroborated by the national regulatory entities of
all countries where the product has already been approved.
Zeitler et al. [16] showed that SP-10 peptide was highly
active against a broad spectrum of bacteria, but showed low
haemolytic activity and a very low phytotoxicity to plant
protoplasts and therefore seemed to be well suited as a plant
protection agent. Ebbensgaard et al. [18] reported that Sub-
5 peptide had no minimal haemolytic activity, indicating
that it might be safe to use at the concentrations needed to
exert antibacterial activity. In conjunction with both the
high efficacy and low toxicity profile, allied to a future
deeper and more focused development of an appropriate
formulation, this may result in a potent protein-based bio-
pesticide for use in agriculture.
The results presented in this study are an important break-
through and may represent a new approach in the design of
new bi-functional antimicrobial peptides with major poten-
tial for use in medicine, food safety and agriculture. In con-
clusion, we designed, engineered and produced fusion
proteins with antimicrobial activity against a range of
human, spoilage and plant-pathogenic bacteria, yeasts and
filamentous fungi.
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